Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.

The present invention is related to a novel pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a process for preparing the same, and a pharmaceutical composition using the same.

The present invention is related to a novel pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a process for preparing the same, and a pharmaceutical composition using the same.

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

##STR00001##

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

##STR00001##

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.

Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.

Disclosed are compounds of Formula (I) to (VIII): ##STR00001##
or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R.sub.3 is a tricyclic heteroaryl group substituted with R.sub.3a and zero to 2 R.sub.3b; and R.sub.i, R.sub.2, R.sub.3a, R.sub.3b, R.sub.4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Disclosed are compounds of Formula (I) to (VIII): ##STR00001##
or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R.sub.3 is a tricyclic heteroaryl group substituted with R.sub.3a and zero to 2 R.sub.3b; and R.sub.i, R.sub.2, R.sub.3a, R.sub.3b, R.sub.4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.